- Posted by ventac
- On November 25, 2019
- 0 Comments
Orbit Genomics (Boulder, CO) November 18, 2019—-
Orbit Genomics Strengthens its Board of Directors with the Appointment of Dr. Morten Søgaard, PhD
Orbit Genomics, developer of the cutting-edge technology platform, OrbiSeq™, that works by incorporating artificial intelligence in its proprietary algorithms to analyze novel genomic markers which uniquely reflect both inherited disease risk and risk acquired from lifestyle and environmental exposures, announced today that Dr. Morten Søgaard, PhD has joined its Board of Directors.
“As VP and Head of Target Sciences at Pfizer, Inc., Dr. Søgaard brings deep experience in genomic technologies for pharmaceutical drug discovery and clinical development. We are thrilled and honored to have Dr. Søgaard join our board. His unique perspective and vast expertise are tremendous assets for our team,” said CEO Dede Willis.
Dr. Søgaard oversees human genetics, functional genomics, computational biology and innovative target exploration academic networks (ITENs) capabilities for identifying and validating novel targets in areas of emerging science of interest to Pfizer R&D. Dr. Søgaard also oversees Pfizer’s companion diagnostic development organization and (before externalizing it) Pfizer’s biobank. He in previous roles guided Pfizer’s investments in platform technologies and oversaw platform technology and oncology licensing (to phase II) and co-led several Pfizer-wide strategy initiatives on Precision Medicine, AI, Gene Therapy.
Dr. Søgaard started his industry career at Pharmacia in Lund, Sweden, where he quickly advanced to section head, protein engineering and responsible for all aspects of next generation immune-oncology antibody therapeutics. In 1998, Dr. Søgaard moved to AstraZeneca to head the Molecular Sciences Department in Mölndal, Sweden, leading about 100 scientists conducting genomics, proteomics, genetics and protein family research. He also headed up AZ’s global nuclear receptor program and was a member of the cardiovascular and GI management team. In 2004 Dr. Søgaard moved to Boehringer Ingelheim in Ridgefield, CT as VP and global head of enabling technology. In this role he helped build a world-wide enabling technology function comprising global technology skill centers (Mab Lead discovery, high throughput protein expression, functional genomics, compound pool optimization, and fragment-based screening), research informatics and an infrastructure for biologics research, and briefly served as Head of R&D Informatics. Dr. Søgaard has ~ 10 years of experience sitting on the global R&D Leadership team at Pfizer and Boehringer.
“His broad and deep insights into diagnostic and therapeutic needs and the potential of various technologies, including OrbiSeq, contributes directly to our strategy for bringing these new technologies to market,” said CSO, Harold “Skip” Garner. Dr. Garner continued, “We extend a warm welcome Morten to the Orbit Genomics family.”